Paratek Pharmaceuticals, Inc. (PRTK)
| Market Cap | 259.04M |
| Revenue (ttm) | 55.43M |
| Net Income (ttm) | -87.27M |
| Shares Out | 46.66M |
| EPS (ttm) | -1.92 |
| PE Ratio | n/a |
| Forward PE | 135.14 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 29 |
| Last Price | $5.42 |
| Previous Close | $5.52 |
| Change ($) | -0.10 |
| Change (%) | -1.81% |
| Day's Open | 5.58 |
| Day's Range | 5.40 - 5.58 |
| Day's Volume | 124,571 |
| 52-Week Range | 4.11 - 11.24 |
-- First BARDA Procurement has been Delivered and Revenue will be Recognized in Second Quarter 2021 -- First BARDA Procurement has been Delivered and Revenue will be Recognized in Second Quarter 2021
GAITHERSBURG, Md.--(BUSINESS WIRE)--Adaptive Phage Therapeutics Expands Board Following Series B Financing Led by Deerfield Management
Do you agree with analysts on these penny stocks? The post 9 Hot Penny Stocks To Watch Right Now, Analyst Targets Up To 290% appeared first on Penny Stocks to Buy, Picks, News and Information | PennySto...
The company reduced its 2021 revenue outlook.
Paratek Pharmaceuticals Inc (NASDAQ: PRTK) has initiated Phase 2b trial evaluating Nuzyra (omadacycline) for Nontuberculous Mycobacterial (NTM) Pulmonary Disease caused by Mycobacterium abscessus comple...
-- U.S.-Based Sites Ready to Begin Enrolling Patients, Placebo-Controlled Study Evaluating NUZYRA Efficacy at 12 Weeks of Treatment
BOSTON, June 10, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving...
The company gets off to a roaring start in June with an important FDA nod.
BOSTON, June 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving...
The FDA has approved Paratek Pharmaceuticals Inc's (NASDAQ: PRTK) supplemental marketing application for the oral-only dosing regimen of Nuzyra for Community-Acquired Bacterial Pneumonia (CABP). The app...
- Oral-only dosing for the Treatment of CABP Expands the Commercial Opportunity for Primary Care Promotion
BOSTON, May 26, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving ...
Paratek (PRTK) delivered earnings and revenue surprises of -77.27% and -49.96%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of Paratek Pharmaceuticals (NASDAQ:PRTK) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share rose 40.91% year over year to ($0.39), which missed the es...
-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $13.2 Million in the First Quarter 2021; 6% Increase Over the Fourth Quarter 2020 -- BARDA has Initiated the First Procurement of NUZYRA Valued at ~...
Paratek (PRTK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Paratek (PRTK) delivered earnings and revenue surprises of -712.50% and -59.53%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
-- NUZYRA Generated Net U.S. Sales of $12.4 Million in the Fourth Quarter 2020; a 14% Increase Over the Third Quarter 2020 -- NUZYRA Expansion into the Primary Care Setting in 2021
BOSTON, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving...
BOSTON, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving...
Gracell Biotech completed a $209 million NASDAQ IPO for its next-gen CAR-T treatments. Zai Lab acquired greater China rights to an argenx SE novel treatment for autoimmune indications in a deal worth up...
Proceeds Used to Prepay Outstanding Loan with Hercules Capital, Inc. Proceeds Used to Prepay Outstanding Loan with Hercules Capital, Inc.
The Bruce Fund, co-managed by founder Robert Bruce (Trades, Portfolio) and his son Jeff, revealed in November that its top trades included a new position in Chiasma Inc. (NASDAQ:CHMA), position boosts i...
BOSTON, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving...
Nuzyra launch trajectory is top of class compared with other antibiotics. BARDA deal signed late 2019 is worth $285M.
BOSTON, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving...
Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q3 2020 Results - Earnings Call Transcript
Paratek (PRTK) delivered earnings and revenue surprises of 24.59% and 14.88%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Paratek (PRTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BOSTON, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving...
Key Highlights Include Data on NUZYRA as an Alternative to Standard of Care to Reduce Clostridioides Difficile Infections and Real-World Experience with NUZYRA for Nontuberculous Mycobacterial and MDR/X...
Paratek Pharmaceuticals: Undervalued Antibiotics Play With A Fighting Chance
BOSTON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-sav...
BOSTON, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-sav...
Paratek Pharmaceuticals, Inc.(PRTK) CEO Evan Loh on Q2 2020 Results - Earnings Call Transcript
Paratek (PRTK) delivered earnings and revenue surprises of -278.57% and -72.84%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Paratek Pharmaceuticals (NASDAQ:PRTK) rose 2.3% in pre-market trading after the company reported Q2 results.
BOSTON, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savi...
BOSTON, July 28, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savi...
Paratek (PRTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BOSTON, May 29, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savin...
Paratek Plods Along
Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q1 2020 Results - Earnings Call Transcript
Paratek (PRTK) delivered earnings and revenue surprises of 20.48% and 2.15%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Paratek Pharmaceuticals (NASDAQ:PRTK) rose 2.1% in pre-market trading after the company reported Q1 results.
As of late, it has definitely been a great time to be an investor Paratek Pharmaceuticals
Purchase of the first 2,500 treatment courses of NUZYRA expected in the first half of 2020 Purchase of the first 2,500 treatment courses of NUZYRA expected in the first half of 2020
Paratek Revenue Ramp-Up Is Underappreciated By The Market And Should Drive Stock Price Gains
Paratek Pharmaceuticals: A Bright 2020 Ahead
Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q4 2019 Results - Earnings Call Transcript
About PRTK
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracy... [Read more...]
| Industry Biotechnology | Founded 1996 |
| CEO Evan Loh | Employees 196 |
| Stock Exchange NASDAQ | Ticker Symbol PRTK |
Financial Performance
In 2020, PRTK's revenue was $46.92 million, an increase of 183.63% compared to the previous year's $16.54 million. Losses were -$96.54 million, -25.04% less than in 2019.
Analyst Forecasts
According to 5 analysts, the average rating for PRTK stock is "Strong Buy." The 12-month stock price forecast is 19.60, which is an increase of 261.62% from the latest price.